Page last updated: 2024-12-09

2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole is a chemical compound with the following structure:

![2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=10478900&t=l&w=200&h=200)

This compound is not widely researched or studied. There is limited information available about its properties and applications. It is likely a synthetic compound and may not have any significant biological or industrial uses.

**Why is it important for research?**

While the specific compound itself may not be of significant research interest, the **structural features** it presents can be relevant to various research areas. For example:

* **1,3,4-oxadiazole ring:** This heterocyclic ring system is found in various compounds with biological activities, including antifungal, antibacterial, and anticancer properties. Researchers may explore the synthesis and modification of this ring system to develop new drugs or agrochemicals.
* **Furanyl ring:** This ring system is common in natural products and is known for its diverse biological activities. Researchers may be interested in studying the interaction of the furanyl ring with the oxadiazole ring and its potential impact on the compound's properties.
* **Ethoxy groups:** These substituents are often used to modify the lipophilicity and solubility of compounds, which can be important for drug development and other applications.

In conclusion, while the specific compound 2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole might not be a major subject of research, the structural features it possesses could be relevant to ongoing research in various fields like medicinal chemistry, organic synthesis, and materials science.

Cross-References

ID SourceID
PubMed CID648294
CHEMBL ID1325231
CHEBI ID122140

Synonyms (16)

Synonym
smr000001659
MLS000031524 ,
OPREA1_465834
OPREA1_728146
ASN 02223521
2-(3,4-diethoxy-phenyl)-5-furan-2-yl-[1,3,4]oxadiazole
CHEBI:122140
AKOS000730424
2-(3,4-diethoxyphenyl)-5-(furan-2-yl)-1,3,4-oxadiazole
HMS2389L13
CHEMBL1325231
bdbm36840
2-(3,4-diethoxyphenyl)-5-(2-furyl)-1,3,4-oxadiazole
2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole
cid_648294
Q27210783
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency5.55280.01846.806014.1254AID624172; AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency28.18380.100020.879379.4328AID588456
BRCA1Homo sapiens (human)Potency11.22020.89137.722525.1189AID624202
ClpPBacillus subtilisPotency22.38721.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency12.27980.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.58490.28189.721235.4813AID2326
P53Homo sapiens (human)Potency89.12510.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.54810.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.00000.039816.784239.8107AID995
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency7.07950.00798.23321,122.0200AID2546
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)IC50 (µMol)67.53600.13430.86462.1450AID588797
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]